This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

The Effect Of Wound Irrigation With Irrisept™ Delivery System On Abscess Healing In Patients Presenting To The Emergency Department

This study has been terminated.
(Study did not accrue the required number of study subjects.)
Sponsor:
Collaborator:
Irrimax Corporation
Information provided by (Responsible Party):
University of Florida
ClinicalTrials.gov Identifier:
NCT01302548
First received: September 29, 2010
Last updated: February 28, 2014
Last verified: February 2014
Results First Received: September 9, 2013  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Participant, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Condition: Abscess
Interventions: Device: IRRISEPT
Procedure: Usual Care

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
IRRISEPT Device containing sterile water and chlorhexidine gluconate (CHG)
Usual Care The usual care method will either be the saline irrigation or incision and drainage depending on the physicians discretion.

Participant Flow:   Overall Study
    IRRISEPT   Usual Care
STARTED   14   19 
COMPLETED   12   18 
NOT COMPLETED   2   1 
Lost to Follow-up                2                1 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
IRRISEPT Device containing sterile water and chlorhexidine gluconate (CHG)
Usual Care The usual care method will either be the saline irrigation or incision and drainage depending on the physicians discretion.
Total Total of all reporting groups

Baseline Measures
   IRRISEPT   Usual Care   Total 
Overall Participants Analyzed 
[Units: Participants]
 14   19   33 
Age 
[Units: Participants]
     
<=18 years   0   2   2 
Between 18 and 65 years   14   17   31 
>=65 years   0   0   0 
Age 
[Units: Years]
Mean (Standard Deviation)
 32.42  (9.04)   24.83  (9.81)   27.87  (10.08) 
Gender 
[Units: Participants]
     
Female   5   10   15 
Male   9   9   18 
Region of Enrollment 
[Units: Participants]
     
United States   14   19   33 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Abscess Healing Based on Abscess Measurement Scale   [ Time Frame: 48 hours ]

2.  Secondary:   Number of Patients Prescribed Oral Antibiotics   [ Time Frame: 48 hours ]

3.  Secondary:   Abscess Measurement Using a Abscess Measurement Scale in Methicillin-resistant Staphylococcus Aureus (MRSA) Positive Patients.   [ Time Frame: 48 hours ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Results Point of Contact:  
Name/Title: Richard F Petrik, MD
Organization: University of Florida
phone: 352-265-5911
e-mail: rpetrik@ufl.edu



Responsible Party: University of Florida
ClinicalTrials.gov Identifier: NCT01302548     History of Changes
Other Study ID Numbers: 20101227
Study First Received: September 29, 2010
Results First Received: September 9, 2013
Last Updated: February 28, 2014